A Phase 1 interventional study of Period 1 and Period 2 in Healthy Volunteers, sponsored by Daewoong Pharmaceutical Co. LTD.. Not yet recruiting. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-23.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment
This study aims to evaluate the safety and pharmacokinetic characteristics after administration of DWJ1589 and DWC202315 in healty adult volunteers.
The study design is a Randomized, Open-label, Oral, Single-dose, 2 × 4 crossover study. The patients were randomly assigned to each group. Primary endpoint was Cmax and AUClast of DWJ1589 and DWC202315. Secondary endpoints were AUCinf, AUClast/AUCinf, Tmax and t1/2 of DWJ1589 and DWC202315.
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 196 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
T: DWJ1589 R: DWC202315
Drug: Period 1 · Drug: Period 2 · Drug: Period 3 · Drug: Period 4
T: DWJ1589 R: DWC202315
Drug: Period 1 · Drug: Period 2 · Drug: Period 3 · Drug: Period 4
DWJ1589 or DWC202315
DWJ1589 or DWC202315
DWJ1589 or DWC202315
DWJ1589 or DWC202315
The maximum serum concentration(Cmax) of DWJ1589 and DWC202315
Cmax of DWJ1589 and DWC202315
Time frame: At pre-dose (0 hour), and post-dose 0.83 to 72 hour.
The Area under the curve(AUC)last of DWJ1589 and DWC202315
AUClast of DWJ1589 and DWC202315
Time frame: At pre-dose (0 hour), and post-dose 0.83 to 72 hour.
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daewoong Pharmaceutical Co. LTD.